Bristol Myers Squibb Company $BMY Shares Sold by Commonwealth Equity Services LLC

Key Points

• Commonwealth Equity Services cut its Bristol Myers Squibb stake by 11.1% in the third quarter, selling 108,592 shares; it held 866,982 shares valued at about $54.1 million afterward.
• Bristol Myers Squibb beat quarterly estimates, reporting adjusted EPS of $1.35 versus $1.10 expected and revenue of $13.07 billion, up 6.9% year over year.
• Analysts’ consensus rating was Hold, with an average price target of $65.46. The company’s annualized dividend was $2.52 per share, a yield of about 4.1%.

Commonwealth Equity Services LLC reduced its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 11.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 866,982 shares of the biopharmaceutical company's stock after selling 108,592 shares during the period. Commonwealth Equity Services LLC's holdings in Bristol Myers Squibb were worth $54,100,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in BMY. BlackRock Inc. boosted its position in Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock worth $10,393,783,000 after acquiring an additional 8,702,106 shares during the period. State Street Corp raised its holdings in shares of Bristol Myers Squibb by 7.3% during the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company's stock valued at $6,093,755,000 after purchasing an additional 7,192,724 shares in the last quarter. Primecap Management Co. CA bought a new position in Bristol Myers Squibb during the second quarter valued at about $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Bristol Myers Squibb by 0.5% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company's stock worth $1,315,984,000 after acquiring an additional 119,690 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Bristol Myers Squibb by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company's stock valued at $1,137,847,000 after purchasing an additional 520,330 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Insider Transactions at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the company's stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president owned 16,862 shares of the company's stock, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Julia A. Haller sold 3,800 shares of the stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the transaction, the director directly owned 30,279 shares of the company's stock, valued at $1,916,963.49. This trade represents a 11.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.05% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. UBS Group lowered shares of Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a research note on Wednesday, August 5th. Daiwa Securities Group increased their price objective on Bristol Myers Squibb from $53.00 to $66.00 and gave the company a "neutral" rating in a research report on Tuesday, August 4th. Jefferies Financial Group restated a "buy" rating and issued a $76.00 price objective on shares of Bristol Myers Squibb in a research note on Monday, October 12th. Roth Capital started coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a "buy" rating and a $75.00 price objective on the stock. Finally, Truist Financial set a $70.00 target price on shares of Bristol Myers Squibb in a research report on Friday, October 30th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $65.46.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
• Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
• Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
• Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
• Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Bristol Myers Squibb Stock Performance

BMY opened at $62.20 on Friday. The stock has a market cap of $127.15 billion, a PE ratio of 13.79, a P/E/G ratio of 0.32 and a beta of 0.20. The company has a current ratio of 1.59, a quick ratio of 1.44 and a debt-to-equity ratio of 1.79. Bristol Myers Squibb Company has a 1 year low of $45.26 and a 1 year high of $68.64. The stock's 50 day simple moving average is $62.34 and its 200-day simple moving average is $60.11.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, beating analysts' consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The business had revenue of $13.07 billion during the quarter, compared to analyst estimates of $12.72 billion. During the same period in the prior year, the company posted $1.63 earnings per share. Bristol Myers Squibb's revenue was up 6.9% on a year-over-year basis. Sell-side analysts forecast that Bristol Myers Squibb Company will post 6.45 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were paid a $0.63 dividend. The ex-dividend date was Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. Bristol Myers Squibb's dividend payout ratio is currently 55.88%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company's medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.